141 related articles for article (PubMed ID: 9094112)
1. Chimeric protein cytotoxic against KS tumors.
Marshall A; Castellino A
Nat Biotechnol; 1997 Apr; 15(4):304. PubMed ID: 9094112
[No Abstract] [Full Text] [Related]
2. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model.
Husain SR; Kreitman RJ; Pastan I; Puri RK
Nat Med; 1999 Jul; 5(7):817-22. PubMed ID: 10395328
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
Husain SR; Puri RK
Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
[TBL] [Abstract][Full Text] [Related]
4. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK
Clin Cancer Res; 1997 Feb; 3(2):151-6. PubMed ID: 9815666
[TBL] [Abstract][Full Text] [Related]
5. Recombinant toxins.
Kreitman RJ; Pastan I
Adv Pharmacol; 1994; 28():193-219. PubMed ID: 8080817
[No Abstract] [Full Text] [Related]
6. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
8. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.
Joshi BH; Puri RK
Protein Expr Purif; 2005 Feb; 39(2):189-98. PubMed ID: 15642470
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
FitzGerald DJ; Pastan I
Biochem Soc Trans; 1992 Nov; 20(4):731-4. PubMed ID: 1487051
[No Abstract] [Full Text] [Related]
10. Targeted therapy of cancer with recombinant immunotoxins.
Pastan I
Biochim Biophys Acta; 1997 Oct; 1333(2):C1-6. PubMed ID: 9395287
[No Abstract] [Full Text] [Related]
11. Targeting AIDS-Kaposi's sarcoma.
Mesri EA
Nat Med; 1999 Jul; 5(7):738-9. PubMed ID: 10395315
[No Abstract] [Full Text] [Related]
12. Clinical trials of targeted toxins.
Frankel AE; Tagge EP; Willingham MC
Semin Cancer Biol; 1995 Oct; 6(5):307-17. PubMed ID: 8562908
[TBL] [Abstract][Full Text] [Related]
13. New AIDS drugs take careful aim.
Palca J
Science; 1989 Dec; 246(4937):1559-60. PubMed ID: 2595368
[No Abstract] [Full Text] [Related]
14. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
[TBL] [Abstract][Full Text] [Related]
15. The interleukin-2 receptor: a target for immunotherapy.
Waldmann TA; Goldman C; Top L; Grant A; Burton J; Bamford R; Roessler E; Horak I; Zaknoen S; Kasten-Sportes C
Adv Exp Med Biol; 1992; 323():57-66. PubMed ID: 1485565
[No Abstract] [Full Text] [Related]
16. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK
Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919
[TBL] [Abstract][Full Text] [Related]
17. Midwest symposium seeks therapeutic answers to global AIDS problem.
Goldsmith MF
JAMA; 1990 Jan; 263(3):345-6. PubMed ID: 2104639
[No Abstract] [Full Text] [Related]
18. Quantification of immunotoxin number for complete therapeutic response.
Kreitman RJ
Methods Mol Biol; 2001; 166():111-23. PubMed ID: 11217362
[No Abstract] [Full Text] [Related]
19. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
[TBL] [Abstract][Full Text] [Related]
20. Targeting growth factor receptors with fusion toxins.
Kreitman RJ; FitzGerald D; Pastan I
Int J Immunopharmacol; 1992 Apr; 14(3):465-72. PubMed ID: 1319965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
